BofA lowered the firm’s price target on Integra LifeSciences to $42 from $45 and keeps an Underperform rating on the shares following the Q4 revenue and EPS miss compared to the Street and 2024 guidance that came in below consensus. The Boston relaunch appears on track, but the pending retirement of the CEO “adds another potential distraction,” says the firm, which sees risk to Integra’s expected steep revenue growth ramp.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IART:
- Integra Lifesciences Announces CEO Transition and New Executive Chairman
- Integra LifeSciences CEO Jan De Witte to retire by the end of 2024
- Integra LifeSciences sees Q1 adjusted EPS 53c-57c, consensus 74c
- Integra LifeSciences sees FY24 adjusted EPS $3.15-$3.25, consensus $3.44
- Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
